RBRoberto Baratta

Roberto Baratta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roberto Baratta has a total of 221 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Capturing human-machine interplay in automated insulin delivery systems through day-to-day variability of the automated correction index (ACI-V%)

    by Andrea Tumminia, Giuseppe Papa, Rossella Cannarella, Francesco Galeano, Vittorio Oteri, Vincenzo Amato, Roberto Baratta, Rosita A. Condorelli, Roberto Palazzolo, Carmelo Gusmano, et al.

  • Open Access

    Optimizing the use of the Omnipod 5 system in adults with type 1 diabetes: an Italian expert Delphi consensus

    by Sergio Di Molfetta, Dario Pitocco, Roberta Assaloni, Roberto Baratta, Federico Boscari, Lutgarda Bozzetto, Lucia Briatore, Dalia Crazzolara, Alessandra Dei Cas, Ilaria Dicembrini, et al.

  • Open Access

    The CRUMB study: closed-loop response to unannounced mixed and carbohydrates-rich breakfasts. A randomized controlled crossover pilot-study in a cohort of adolescents with type 1 diabetes

    by Donatella Lo Presti, Salvatore Scirè Calabrisotto, Letizia Grazia Tomaselli, Giulia Pezzino, Francesco Frasca, Roberto Baratta, Laura Sciacca, Concetta Latina, Nadia La Spina, Francesco Galeano, et al.

    Purpose: Unannounced meals pose a major challenge to type 1 diabetes patients. This study compared the performance of two automated insulin delivery (AID) algorithms, the Medtronic MiniMed 780G’s proportional-integral-derivative (PID) and the Tandem t: slim X2’s model predictive control (MPC), following unannounced breakfasts (ClinicalTrials.gov identifier: NCT07455643, retrospectively registered the 3rd of February 2026). Methods: In a randomized crossover study, we enrolled 20 children between 11 and 18 years using the MiniMed 780G or the Tandem t: slim X2 AID system. Endpoints included 2-hour and 4-hour blood glucose difference (ΔBG), glucose peak, time to peak, and time spent above (TAR), below (TBS), in range (TIR), and in tight range (TITR). Two meals were tested: a carbohydrate (CHO) meal and a mixed one, both containing 30 g of carbohydrates, and additional 15 g proteins for the mixed meal. Announced (AM) and unannounced (UM) meals were analyzed. Results: AM, compared to UM, showed significant higher 2-hourΔBG; conversely 4-hourΔBG did not differ significantly. In CHO AM, algorithms were comparable. In mixed AM, PID gained lower peaks and TAR, with higher TIR and TITR. In UM, PID obtained lower 2-hourΔBG than MPC, with reduced peak, TAR, and improved TIR and TITR. Differences in 4-hourΔBG and time-at-peak were not significant. Conclusion: Both AID algorithms mitigated postprandial glycemia and returned glucose to baseline levels within 4 h without safety concerns. The PID demonstrated higher reactivity to unannounced meals, while performances were comparable when meal boluses were properly announced. ClinicalTrials.gov identifier: NCT07455643.

  • Open Access

    Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety

    by Federica Vinciguerra, Carla Di Stefano, Fabio Guccione, Claudia Degano, Stefania Nigro, Roberto Baratta, Luigi Piazza, Giuseppe Navarra, Lucia Frittitta

    Background: Recurrent weight gain after bariatric surgery (BS) or endoscopic bariatric therapy (EBT) remains a long-term clinical challenge, potentially undermining long-term treatment success. Tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown promising results in obesity treatment, but data regarding its use in post BS or EBT recurrent weight gain are limited. Methods: This observational cohort study evaluated the effectiveness and safety of tirzepatide in patients with recurrent weight gain after BS or EBT. Anthropometric data, BMI categories, and adverse events were collected at baseline and after 24 weeks of treatment. Results: A total of 34 patients (26 females, 8 males) who experienced recurrent weight gain after BS ( n = 32) or EBT ( n = 2) were treated with once-weekly subcutaneous tirzepatide (dosing range 2.5–10 mg/week). After 24 weeks, the mean percentage total body weight loss (%TBWL) was 18.1 ± 5.6% ( p < 0.0001), with a significant reduction in waist circumference ( p < 0.0001). Most patients shifted to lower BMI categories, with the majority reaching overweight or normal weight status. Adverse events were exclusively gastrointestinal (constipation, diarrhea, nausea), generally mild, and did not lead to treatment discontinuation. Conclusion: Preliminary evidence suggests that tirzepatide is associated with significant weight loss and good tolerability in this observational cohort for managing recurrent weight gain after bariatric surgery and endoscopic bariatric therapy. These findings suggest a potential role for tirzepatide as a valuable nonsurgical option in the multidisciplinary management of patients experiencing recurrent weight gain after bariatric procedures.


  • Open Access

    Type 2 diabetes mellitus is associated with asymptomatic acute abdomen among elderly patients admitted to acute tertiary care hospital wards

    by Andrea Tumminia, Raffaella Romano, Francesco Frasca, Francesco Galeano, Roberto Baratta, Vittorio Oteri, Alessia Longo, Lucia Frittitta, Rosario Le Moli, Tommaso Piticchio, et al.

    Background: Pain may be absent in a substantial proportion of elderly patients with acute abdominal conditions. This study explored the association between type 2 diabetes mellitus (T2DM) and asymptomatic presentation. Methods: We conducted a cross-sectional analysis of 215 patients aged ≥ 65 years admitted with acute abdominal conditions. Demographic, clinical, and laboratory data were extracted from medical records. Descriptive statistics and multivariable logistic regression were used to identify associative predictors of asymptomatic acute abdomen (AAA). Results: The median age was 82 years [77–86]; 54.4% ( n = 117) were female; 31.2% ( n = 67) had T2DM. Overall, 33.5% ( n = 72) presented without abdominal pain. T2DM prevalence was higher in AAA than symptomatic patients (44.4% vs. 24.5%, p < 0.01). In multivariable analysis, T2DM (OR 1.95, 95% CI 1.10–3.45, p = 0.02), lower heart rate (OR 0.83, 95% CI 0.71–0.96, p = 0.01), and absence of fever (OR 0.50, 95% CI 0.26–0.95, p = 0.03) were associated with AAA. Among patients with T2DM, longer diabetes duration (12.5 years [10.5–14.5] vs. 8.8 years [5.0–11.0]; p < 0.01) and higher HbA1c (8.2% [7.2–8.7] vs. 7.5% [6.8–7.6]; p = 0.02) were associated with asymptomatic presentation. Conclusions: Asymptomatic acute abdomen is common among elderly patients. Long-standing and poorly controlled T2DM is associated with absent pain. Prospective studies are needed to clarify causal mechanisms, and early glyco-metabolic assessment may aid recognition of at-risk patients.


  • Open Access

    The automated correction index (ACI), a novel report-derived metric correlated to glucose control and variability in patients with type 1 diabetes on advanced hybrid closed loop therapy

    by Andrea Tumminia, Gaetano Maria Santoro, Vittorio Oteri, Francesco Galeano, Roberto Baratta, Damiano Gullo, Lucia Frittitta, Laura Sciacca, Rosario Le Moli, Tommaso Piticchio, et al.


  • Open Access

    Clinical Assessment of Altered Eating Behaviors in People with Obesity Using the EBA-O Questionnaire

    by Vittorio Oteri, Laura Contrafatto, Gaetano Maria Santoro, Ignazio Barca, Andrea Tumminia, Federica Vinciguerra, Lucia Frittitta, Francesco Frasca, Laura Sciacca, Roberto Baratta

    Background/Objectives: Over the past decade, numerous studies have explored the bidirectional relationship between obesity and mental health, mainly eating disorders (EDs). This study aimed to assess the prevalence and characteristics of altered eating behaviors (AEBs) in a cohort of people with obesity (PwO) using the validated Eating Behaviors Assessment for Obesity (EBA-O). Methods: We conducted a cross-sectional study from May 2023 to April 2024, recruiting consecutive PwO seeking weight loss. Participants completed the 18-item EBA-O questionnaire, which focuses on five primary eating behaviors: night eating, food addiction, sweet eating, hyperphagia, and binge eating. Unlike other validated tools, the EBA-O is specifically designed to capture these behaviors in PwO and is easy for patients to self-administer. We also collected sociodemographic and clinical data. Results: A total of 127 participants were included (76 women, median age 52 years, median BMI 42.9 kg/m2). We found a significant prevalence of AEBs: 33.1% for sweet eating, 23.6% for hyperphagia, 15.7% for food addiction, 14.2% for binge eating, and 7.1% for night eating. The EBA-O scores correlated positively with BMI (r = 0.201, p = 0.024) and increased across BMI categories (p = 0.001). Males had higher scores for night eating and hyperphagia (p = 0.01), and active smokers had higher hyperphagia scores (p = 0.043) than ex-smokers and non-smokers. The night eating scores were inversely correlated with sleep hours (r = −0.197, p = 0.026), and food addiction was positively correlated with age (r = 0.261, p = 0.003); conversely, hyperphagia (r = −0.198, p = 0.025) and binge eating (r = −0.229, p = 0.010) were inversely correlated with age. PwO without diabetes had higher scores for food addiction (p = 0.01) and binge eating (p = 0.004) compared to those with diabetes. Conclusions: These results highlight the potential to characterize PwO based on their AEBs, offering new opportunities to tailor treatment strategies for PwO by targeting specific eating behaviors.


  • Open Access

    Severe Late‐Onset Abiraterone‐Induced Hypokalemia in a Diabetic Patient With Concomitant Adrenal Gland Incidentaloma: A Diagnostic Challenge

    by Andrea Tumminia, Francesco Galeano, Vittorio Oteri, Federica Gambero, Stefania Panebianco, Roberto Baratta, Daniela Leonardi, Ilenia Marturano, Dario Giuffrida, Francesco Frasca, et al.

    Prostate cancer is the most prevalent cancer among men in Western countries and is commonly managed by androgen deprivation therapy for locally advanced or metastatic stages. Even if initially effective, most patients eventually develop resistance to this treatment. Approved in 2011 for castration‐resistant prostate cancer, abiraterone acetate inhibits the CYP17A1 enzyme, which is crucial in androgen and cortisol synthesis. This inhibition disrupts feedback on adrenocorticotropic hormone (ACTH), causing mineralocorticoid excess syndrome (MES), which is characterized by fluid retention, hypokalemia, and hypertension. MES can persist even with glucocorticoid supplementation, as observed in some cases. This study describes the case of a 68‐year‐old male with prostate cancer who developed severe, treatment‐resistant hypokalemia after 6 years of abiraterone and prednisone therapy. The patient presented with poorly controlled diabetes and notable hypokalemia despite oral and parenteral potassium supplementation. Imaging revealed an adrenal adenoma; however, low renin and aldosterone levels suggested that abiraterone‐induced MES, rather than primary aldosteronism, was responsible for his hypokalemia. The main therapy adjustment consisted of switching prednisone to dexamethasone to enhance ACTH suppression, effectively resolving the patient’s hypokalemia. This case underscores the need for MES monitoring in patients on abiraterone, as MES can develop or worsen over time. Physicians should consider dexamethasone over prednisone in persistent MES cases, always monitoring also for the risk of developing Cushing syndrome. Given the rising prostate cancer incidence, clinicians must remain vigilant for MES‐related complications with abiraterone, including delayed‐onset severe hypokalemia.


  • Open Access

    Influence of Mediterranean Diet on Sexual Function in People with Metabolic Syndrome: A Narrative Review

    by Vittorio Oteri, Francesco Galeano, Stefania Panebianco, Tommaso Piticchio, Rosario Le Moli, Lucia Frittitta, Veronica Vella, Roberto Baratta, Damiano Gullo, Francesco Frasca, et al.

    Metabolic syndrome (MS), a cluster of cardiometabolic disorders, and sexual dysfunction are two conditions that impact a large proportion of the general population. Although they can occur independently, they are frequently linked and significantly affect people’s quality of life. In recent years, research has increasingly focused on the importance of diet, particularly the Mediterranean diet (MD), in modulating sexual function due to its anti-inflammatory, antioxidant, and vasodilatory properties. In this narrative review, we examined the relationship between MS and sexual function in both men and women, with a special emphasis on the MD’s therapeutic efficacy in improving sexual dysfunction. In men, MD has been shown to ameliorate erectile dysfunction, as well as several sperm parameters, perhaps leading to improved fertility. On the other hand, adherence to MD has been demonstrated to partially recover several sexual dysfunctions in women, such as those related to their menstrual cycle, menopause, endometriosis, and polycystic ovary syndrome. These favorable effects of MD have been demonstrated in both sexes also among people affected by MS. However, more targeted studies are needed to validate these data for different dietary approaches as well.


  • Open Access

    Excessive generalized and visceral adiposity is associated with a higher prevalence of diabetic retinopathy in Caucasian patients with type 2 diabetes

    by Andrea Tumminia, Agostino Milluzzo, Nunzia Carrubba, Federica Vinciguerra, Roberto Baratta, Lucia Frittitta